United States: Off-Label Use: Protected Commercial Speech Or Misbranding?

For years, the Food and Drug Administration has recognized that there is a prevalence of off-label use of drugs approved by FDA for specific indications, there is clinical relevance and value from such off-label use, and there is a large amount of information about both on- and off-label uses of such drugs available even with a limited ability by manufacturers to disseminate this information. This recognition requires a balancing by FDA between enforcing the Food, Drug, and Cosmetic Act's regulations prohibiting promotion of off-label use and permitting dissemination of off-label information to healthcare professionals for use in treating their patients. Key to this balancing act is FDA's position that any off-label discussions by manufacturers constitutes "misbranding" and are in violation of FDCA. Recent success by manufacturers establishing that disclosure of truthful and non-misleading information about off-label use of their products is protected commercial speech has thrown the FDA's balance out of whack. While currently limited in scope, such challenges may change the FDA's enforcement actions to focus more on false and misleading content in such off-label discussions and less on a presumption of "misbranding" based solely on the fact of off-label discussions.

I. FDCA AND MARKETING OF DRUGS

The FDCA and its amendments create the statutory requirement for drugs to be approved for safety and effectiveness for their intended uses before being introduced into commerce.1,2 The FDA has long maintained that manufacturers must market and promote products consistent with the FDA-approved labeling, and therefore off-label use means "misbranded" under the FDCA3. In addition to FDA's own enforcement activities, the Department of Justice, in conjunction with the FDA, have in recent years actively pursued enforcement of misbranding provisions against drug manufacturers by claiming that offlabel promotion by manufacturers has generated increased requests for reimbursement of healthcare claims in violation of the False Claims Act4. With the punitive consequence of exclusion from participation in federal healthcare programs, these misbranding claims have resulted in numerous significant settlements with manufacturers, such as Pfizer in 2009 ($2.3 billion),5 Abbott Laboratories, Inc. in 2012 ($1.5 billion),6 and GlaxoSmithKline LLC in 2012 ($3 billion),7 among others.

II. FDA GUIDANCE ON DISSEMINATION OF OFF-LABEL INFORMATION

The FDA recognizes that off-label uses by healthcare professionals may be important to support public health regardless of their approved indications. In fact, off-label use may be supported in published medical literature and journals and may even constitute the medically recognized standard of care.8 In order to restrict the expansion of offlabel use, FDA issued guidance permitting some limited dissemination of materials related to off-label uses.

A 2009 FDA guidance document describes the process permitting manufacturers to disseminate medical or scientific publications about off-label uses of their products.9 That draft guidance was replaced in February 2014 to specify revised requirements and limitations on when such published materials can be distributed. To avoid misbranding, such materials must: be created by independent experts; contain scientifically sound evaluations; not be false or misleading; not be written by or influenced by a manufacturer; be provided in unabridged form; be distributed separately from promotional information or material; be distributed with FDA-approved labeling; be distributed with a bibliography of publications describing the clinical studies about the off– label use; and be distributed with a prominent statement that the use discussed has not been approved by FDA, including any known risks or safety concerns related to the off-label use.10

In addition to the proactive dissemination of content to physicians and healthcare entities described above, FDA issued a 2011 draft guidance allowing the reactive dissemination of information in response to unsolicited requests for off-label information. Pursuant to such draft guidance, manufacturers may respond to unsolicited requests for information about off-label uses of their products. The responses must be truthful, balanced, and non-misleading, non-promotional, scientific or medical information; limited to the specific request; delivered to the specific individual who requested the information; delivered by medical or scientific personnel independent from the sales and marketing departments; and include any FDArequired labeling.11

III. RECENT CHALLENGES ON FIRST AMENDMENT GROUNDS

While the existing FDA guidance provides a mechanism for sharing off-label information, the restrictions in such guidance have frustrated the ability to make the information available in a timely and concise manner. Some manufacturers, emboldened by recent court rulings, have pursued constitutional challenges to these restrictions based on first amendment protected speech grounds. In a December 2012 decision, the Second Circuit, in United States v. Caronia,12 vacated the conviction of a pharmaceutical sales representative for conspiring to promote a drug for off-label use. Caronia argued that his sales pitch, using truthful and non-misleading information, is protected speech under the First Amendment. The court agreed, and because there is no specific prohibition against off-label promotion,13 held that the government cannot "prosecute pharmaceutical manufacturers and their representatives under the FDCA for speech promoting the lawful, off-label use of an FDAapproved drug."14

On May 7, 2015, Amarin Pharmaceuticals went on offense, filing a complaint to permit it to share truthful and non-misleading off-label information about its FDA-approved product, Vascepa®, under the First Amendment. Amarin originally sought approval to market Vascepa for treatment of persistently high triglyceride levels. The FDA declined that approval, and Amarin used alternative measures (including special protocol assessments and a separate clinical trial) to extrapolate the clinical safety and effectiveness of the drug for the intended treatment. But, based on the results from three unrelated clinical trials for unrelated cardiovascular products that had found no impact on cardiovascular risk, FDA concluded that these results raised substantial scientific issues about the results of Amarin's clinical trial. FDA also added in its letter to Amarin that the drug would be deemed misbranded if Amarin promoted Vascepa for reduction of triglyceride levels in persons with persistently high triglyceride levels.

Amarin responded by filing a complaint seeking protection that would enable it to make truthful, nonmisleading statements about Vascepa consistent with its clinical trial results.15 Amarin's complaint further alleged that the prescription of Vascepa by physicians is lawful, and the limitation by FDA severely restricts medical professionals' access to information from the source most knowledgeable about the drug.16 The court granted preliminary relief to Amarin, finding that Amarin could engage in truthful and non-misleading speech promoting the off-label use of Vascepa and, under Caronia, such speech may not be the basis of a prosecution for misbranding.

Relying upon the success of Caronia and Amarin, in September, 2015, Pacira Pharmaceuticals filed a complaint seeking declaratory and injunctive relief that FDA's restrictions on Pacira's truthful and non-misleading speech harmed Pacira's commercial interests and ability to advance public health.17 In October 2011, the FDA approved Exparel® for post-surgical pain management based on a demonstration of safety and effectiveness in two clinical trials for soft tissue and hard tissue applications. In September 2014, FDA issued a warning letter to Pacira demanding that it stop providing instructions that imply Exparel is approved for use in procedures other than the two specific applications from the clinical trials. Pacira responded to FDA, outlining its disagreement that the materials violated the FDCA. In July 2015, FDA issued a closing letter regarding Pacira's warning letter, concluding that Pacira's speech was violative of the FDCA which led to the filing of the complaint.

The parties then entered a settlement agreement on December 14, 2015, resulting in a mutual release of claims, a withdrawal of the warning letter with an FDA letter of explanation, a revision of the product labeling and instructions, and a confirmation by FDA that the drug was approved for broad use across various applications, not just for the two procedures originally tested. While the settlement did not respond to the rights of Pacira to discuss off-label uses, it did expressly preserve Pacira's ability to assert constitutional rights related to its Exparel marketing efforts.

In March 2016, Amarin and FDA settled their dispute, and FDA acknowledged (by accepting the court's determination) that Amarin's proposed statements were truthful and nonmisleading. Amarin agreed to assure its communications remained truthful, and FDA agreed to preview up to two proposed communications by Amarin and to provide Amarin with any concerns FDA may have with the communications. The parties agreed to an established dispute resolution process prior to requesting judicial resolution.

IV. FUTURE IMPACT OF CARONIA, AMARIN AND PACIRA

The results in Caronia, Amarin and Pacira undoubtedly support a manufacturer's dissemination of truthful and nonmisleading information on the risks and benefits of the offlabel use of its products and provide potential defenses to enforcement actions by FDA and the DOJ. The FDA's recent acknowledgement and recognition of Amarin's rights to promote off-label use through truthful and non-misleading speech may illustrate a shift in the FDA's enforcement of manufacturer's promotional activities. However, before manufacturers move forward with wholesale promotion of off-label uses of their products based on these recent decisions, it is worthwhile to consider the limitations and specifics of these decisions.

First, as observed by the court in Amarin and agreed to by Amarin in its settlement, a manufacturer should have a process to vet and script in advance the statements it intends to make about a drug's off-label use to assure that its communications remain truthful and non-misleading. These decisions will not protect manufacturers from speech that is false or misleading. Also, manufacturers must remain diligent in reviewing content to be disseminated and ensure that appropriate training is provided to the representatives engaged in discussions about their products, whether sales, marketing or other specialties, to make sure they do not "misbrand" their products. This is emphasized by the FDA's public statements since Caronia that it does not view these decisions as significantly affecting its enforcement of the misbranding provisions of the FDCA,18 even though it will likely cause FDA to be more prudent in its enforcement activities.

Second, the decisions do not protect manufacturers if the government uses the off-label speech as evidence in cases under the False Claims Act, although it will make it more difficult to prove that the lawful, truthful and non-misleading speech caused the submission of a nonreimbursable claim.

Third, while the Caronia decision applies to government prosecution of manufacturers generally in the promotion of lawful, off-label use of an approved drug, it is worth noting that FDA elected not to seek a petition for certiorari, thus leaving the decision somewhat limited. While the settlement in Pacira did serve to preserve Pacira's first amendment rights, the resolution of the matter did not turn as much on the constitutional rights issue as it did on permitting Pacira to rely upon the broad indication issued by FDA in its original approval and preventing the FDA from seeking to limit the approved indications of products without following its own regulations and due process.

These decisions provide some additional latitude to manufacturers to discuss truthful and non-misleading information about their products, but they should not be viewed as providing broad protection to promote off-label uses as constitutionally protected free speech. Manufacturers remain obligated to maintain a review process for any information or material communicated to their customers.

Footnotes

1 US Food Drug & Cosmetic Act, 21 USC 351 (1938)

2 Public L. No 87-781, 76 Stat. 780 (1962)

3 21 USC 331(a)

4 31 U.S.C. 3729, et seq.

5 Press Release, US Department of Justice, Justice Department Announces Largest Health Care Fraud Settlement in Its History, Pfizer to Pay $2.3 Billion for Fraudulent Marketing (September 2, 2009) available at https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history

6 Press Release, Department of Justice, Abbott Labs to Pay $1.5 Billion to Resolve Criminal & Civil Investigations of Off-Label Promotion of Depakote (May 7, 2012), available at http://www.justice.gov/opa/pr/2012/May/12-civ-585.html.

7 Press Release, Department of Justice, GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data (July 2, 2012), available at http://www.justice.gov/opa/pr/2012/July/12-civ-842.html.

8 USFDA, Draft Guidance, Good Reprint Practices for Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices (Jan 2009), at 2.

9 Id.

10 USFDA, Revised Draft Guidance, Distributing Scientific and Medical Publications on Unapproved New Uses – Recommended Practices (February 2014).

11 USFDA, Draft Guidance, Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices (December 2011).

12 703 F.3d. 149 (2d Cir. 2012)

13 Id, at 160.

14 Id, at 169.

15 Amarin Pharma, Inc. v USFDA, 15 Civ. 3588 (S.D.N.Y 2015.), at 26.

16 Id.

17 Pacira Pharmaceuticals, Inc. v. USFDA, 15 Civ. 7055 (S.D.N.Y. 2015)

18 PharmaExec.com, Tom Abrams: Caronia Won't Stop Off-Label Enforcement (January 2013), available at: http://www.pharmexec.com/tom-abrams-caronia-wont-stop-label-enforcement

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.